Abstract

The identification and characterization of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) have provided new insights into LDL metabolism and the causal role of LDL in coronary heart disease (CHD). PCSK9 is a secreted protease that mediates degradation of the LDL receptor by interacting with the extracellular domain and targeting the receptor for degradation. Individuals with loss-of-function mutations in PCSK9 have reduced plasma levels of LDL cholesterol and are protected from CHD; these observations have validated PCSK9 as a therapeutic target and suggested new approaches for the treatment and prevention of CHD.

Original languageEnglish (US)
JournalJournal of Lipid Research
Volume50
Issue numberSUPPL.
DOIs
StatePublished - Apr 2009

Fingerprint

Proprotein Convertases
Coronary Disease
Degradation
LDL Receptors
Metabolism
LDL Cholesterol
Peptide Hydrolases
Plasmas
Mutation
oxidized low density lipoprotein
Proprotein Convertase 9

Keywords

  • Hypercholesterolemia
  • Low density lipoprotein
  • Low density lipoprotein receptor
  • Proprotein convertase subtilisin-like/ kexin type 9

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Endocrinology

Cite this

PCSK9 : A convertase that coordinates LDL catabolism. / Horton, Jay D.; Cohen, Jonathan C.; Hobbs, Helen H.

In: Journal of Lipid Research, Vol. 50, No. SUPPL., 04.2009.

Research output: Contribution to journalArticle

@article{4641aadf9d974216857fd30e3194cf93,
title = "PCSK9: A convertase that coordinates LDL catabolism",
abstract = "The identification and characterization of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) have provided new insights into LDL metabolism and the causal role of LDL in coronary heart disease (CHD). PCSK9 is a secreted protease that mediates degradation of the LDL receptor by interacting with the extracellular domain and targeting the receptor for degradation. Individuals with loss-of-function mutations in PCSK9 have reduced plasma levels of LDL cholesterol and are protected from CHD; these observations have validated PCSK9 as a therapeutic target and suggested new approaches for the treatment and prevention of CHD.",
keywords = "Hypercholesterolemia, Low density lipoprotein, Low density lipoprotein receptor, Proprotein convertase subtilisin-like/ kexin type 9",
author = "Horton, {Jay D.} and Cohen, {Jonathan C.} and Hobbs, {Helen H.}",
year = "2009",
month = "4",
doi = "10.1194/jlr.R800091-JLR200",
language = "English (US)",
volume = "50",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "SUPPL.",

}

TY - JOUR

T1 - PCSK9

T2 - A convertase that coordinates LDL catabolism

AU - Horton, Jay D.

AU - Cohen, Jonathan C.

AU - Hobbs, Helen H.

PY - 2009/4

Y1 - 2009/4

N2 - The identification and characterization of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) have provided new insights into LDL metabolism and the causal role of LDL in coronary heart disease (CHD). PCSK9 is a secreted protease that mediates degradation of the LDL receptor by interacting with the extracellular domain and targeting the receptor for degradation. Individuals with loss-of-function mutations in PCSK9 have reduced plasma levels of LDL cholesterol and are protected from CHD; these observations have validated PCSK9 as a therapeutic target and suggested new approaches for the treatment and prevention of CHD.

AB - The identification and characterization of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) have provided new insights into LDL metabolism and the causal role of LDL in coronary heart disease (CHD). PCSK9 is a secreted protease that mediates degradation of the LDL receptor by interacting with the extracellular domain and targeting the receptor for degradation. Individuals with loss-of-function mutations in PCSK9 have reduced plasma levels of LDL cholesterol and are protected from CHD; these observations have validated PCSK9 as a therapeutic target and suggested new approaches for the treatment and prevention of CHD.

KW - Hypercholesterolemia

KW - Low density lipoprotein

KW - Low density lipoprotein receptor

KW - Proprotein convertase subtilisin-like/ kexin type 9

UR - http://www.scopus.com/inward/record.url?scp=66349126280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66349126280&partnerID=8YFLogxK

U2 - 10.1194/jlr.R800091-JLR200

DO - 10.1194/jlr.R800091-JLR200

M3 - Article

VL - 50

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - SUPPL.

ER -